Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. - Wikidata - awgldk - TriplyDB

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

http://www.wikidata.org/entity/Q33713001

about

The first 30 years of p53: growing ever more complex Orchestrating epigenetic roles targeting ocular tumors Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells.Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA A novel anticancer therapy that simultaneously targets aberrant p53 and Notch activities in tumors Development of dual-activity vectors by co-envelopment of adenovirus and SiRNA in artificial lipid bilayers.Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts.Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells.Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101 Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system AAV-directed muscular dystrophy gene therapy.Oncolytic-adenovirus-expressed RNA interference for cancer therapy.Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells.The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells.A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.SP1 suppresses phorbol 12-myristate 13-acetate induced up-regulation of human regucalcin expression in liver cancer cells.Adenovirus-based strategies enhance antitumor capability through p53-mediated downregulation of MGMT in uveal melanoma.CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma.Targeted silencing of the ADP-ribosyltransferase 3 gene inhibits the migration ability of melanoma cells.

P2860

Q24645732-D7F03621-CEDA-452A-9699-A783D8BFEF95 Q26751251-AFEAF41B-0C13-48D1-9EC1-F8E78C9FF26F Q28482805-AEB1DEB8-D3FB-46D6-A2A1-DC82ED1A251A Q33631459-FCC655D9-147C-445F-9357-7AF5CB2193D5 Q33919629-4383EA98-6E26-4CC0-ABD8-D3A95311B27D Q34076762-27DD5CAA-88B9-4025-8817-24E21E7C8DA5 Q34447293-603C171F-03AE-45B4-B8E0-C3C5A169F74F Q34690551-F2923EC7-914E-401C-83B8-45A00008BBAC Q35054432-FB0CDF4E-5E6A-4728-B9F5-F865F5FEC588 Q36099255-ED7AEF4B-5E52-4430-A30C-C6A095A77345 Q36321693-62789811-A8C1-471D-BC9F-460A36567B51 Q36327007-35B05CC3-82E2-4B51-9367-92611F64063B Q36538951-78F69C88-3172-4B00-93CD-C3F17D002F8F Q37687423-68C8F402-81F1-4A98-AAFB-16C665EA5779 Q37777745-77014437-250D-4808-A3A3-F264CC3ECF70 Q39084351-E03F35F3-E39B-4C4C-B3BA-B8A002E050CA Q39098583-FCC2C4B3-774A-45F6-9B91-F131E44001A3 Q39319420-466BF51D-44B0-438E-B25F-3693948A9C87 Q39396223-ADD6836C-90AC-4B32-B5E9-A155C05F452C Q39756408-4BECBDC4-B32A-4D76-9842-BA7A81EE7222 Q41985299-C94D768B-AD3A-4D14-9293-21CA8BF963E0 Q48813459-33D55492-2972-40AD-9365-74C136345190 Q55027942-D577FD15-C2BA-45DF-8169-A26AEAE4DF51

P2860

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

http://www.wikidata.org/entity/Q33713001

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

@ast

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

@en

type

label

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

@ast

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

@en

prefLabel

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

@ast

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

@en

P1433

Q33713001-1BA7FFC5-B20E-4E02-9CD6-EC17CB0C8E22

P1476

Q33713001-75137294-4D9E-4476-828E-EE0E011504CA

P2093

Q33713001-3301D456-6929-4797-A401-B2D9EE71C25A

Q33713001-5331695D-AEC2-4BB3-9446-0CC9F1364485

Q33713001-627597F2-D1FA-4010-940F-344EC085A7F5

Q33713001-6C96C5D9-E8A2-4E2C-8826-D773EDEAB363

Q33713001-7ACA78F3-A2A3-4B4F-A1BF-AA7CFF15AC6D

Q33713001-BCAA824F-3053-45B8-8660-F5C919CF552A

Q33713001-CFF49895-382C-455C-9FD6-1216B5FC25BD

Q33713001-D2A015C0-23BA-4728-9B60-297C303F9A7D

Q33713001-E7C4220E-F8C7-4C95-B507-EE3B34C9A239

Q33713001-E88D285A-C13D-42D7-962F-BC9C1CB64A93

P2860

Q33713001-0C8D6D6A-F2A6-4157-8CAD-29664F09545E

Q33713001-0C93E42E-08BC-497B-91D9-BA17379C92D0

Q33713001-0E97595F-38D0-4F7A-BE52-159D16AE9165

Q33713001-11E891D0-3F3F-4091-B059-A837E087C211

Q33713001-160532B8-C696-43D5-A88F-D7C07B54A7A9

Q33713001-175F8D8B-2ACB-488B-9AB7-C134F6B972C3

Q33713001-1BDF0CAF-F2E9-4026-B22A-9672F758AE33

Q33713001-305913C8-FF93-40FC-98D7-2546343C0455

Q33713001-30FE54AC-139D-4474-B7A5-4E0AB7F6BD6B

Q33713001-33F7CCF4-1F64-43D4-8F8E-88D385B3054C

P304

Q33713001-508E3B24-EED7-4263-B993-B5CC78205CA0

P31

Q33713001-16A01C2A-C88E-4FBA-8453-68108EF6CE43

P356

Q33713001-AA25D8A7-B0DB-463C-81E1-8EEB21820638

P433

Q33713001-20361566-322C-4AB0-B08B-1AF167E6F11B

P478

Q33713001-54629090-A7D8-4E69-9B21-98048CFCE141

P577

Q33713001-F0FC5B68-9CC7-47B1-BB5B-83D4B74EF019

P5875

Q33713001-9225648A-05D2-4E48-A8D4-C6DF3082C0B5

P698

Q33713001-952A0F96-59BB-4990-A300-1E5083970ECF

P932

Q33713001-642224A6-BFA5-4E6D-9B85-0F7DC820876F

P356

P1433

Molecular Therapy

P1476

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

@en

P2093

Andrew R Hoffman

http://www.w3.org/2001/XMLSchema#string

Beibei Niu

http://www.w3.org/2001/XMLSchema#string

Guanxiang Qian

http://www.w3.org/2001/XMLSchema#string

Haibo Wang

http://www.w3.org/2001/XMLSchema#string

He Zhang

http://www.w3.org/2001/XMLSchema#string

Ji-Fan Hu

http://www.w3.org/2001/XMLSchema#string

Jian Lu

http://www.w3.org/2001/XMLSchema#string

Jianjun Zhang

http://www.w3.org/2001/XMLSchema#string

Shengfang Ge

http://www.w3.org/2001/XMLSchema#string

Xianqun Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Viruses and Apoptosis

p53 has a direct apoptogenic role at the mitochondria

Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

Antisense therapy of hematologic malignancies.

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection.

ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

siRNA-mediated gene silencing in vitro and in vivo.

Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

Genasense (Genta Inc).

P304

57-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2008.236

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23482469

http://www.w3.org/2001/XMLSchema#string

P698

19018252

http://www.w3.org/2001/XMLSchema#string

P932

2834989

http://www.w3.org/2001/XMLSchema#string